Abstract
Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other neurotoxic events. A major complication in identifying effective treatment targets is the frequent co-occurrence of multiple neurodegenerative processes, occurring either in parallel or sequentially. The path towards developing effective treatments for Alzheimer’s disease (AD) and other dementias has been relatively slow and until recently has focused on disease symptoms. Aducanumab and lecanemab, recently approved by the FDA, are meant to target disease structures but have only modest benefit on symptom progression and remain unproven in reversing or preventing dementia. A third, donanemab, appears more promising but awaits FDA approval. Ongoing trials include potential cognition enhancers, new combinations of known drugs for synergistic effects, prodrugs with less toxicity, and increasing interest in drugs targeting neuroinflammation or microbiome. Scientific and technological advances offer the opportunity to move in new therapy directions, such as modifying microglia to prevent or suppress underlying disease. A major challenge, however, is that underlying comorbidities likely influence the effectiveness of therapies. Indeed, the full range of comorbidity, today only definitively identified postmortem, likely contributes to failed clinical trials and overmedication of older adults, since it is difficult to exclude (during life) people unlikely to respond. Our current knowledge thus signals that a paradigm shift towards individualized and multimodal treatments is necessary to effectively advance the field of dementia therapeutics.
Similar content being viewed by others
References
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100.
Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22:2314–24.
Sachdev P, Kalaria R, O’Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. Alzheimer Dis Assoc Disord. 2014;28:206–18.
Ducharme S, Dols A, Laforce R, et al. Recommendations to distinguish behavioural variant frontotemporal dementia from psychiatric disorders. Brain. 2020;143:1632–50.
Boyle PA, Yu L, Leurgans SE, et al. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol. 2019;85:114–24.
Schneider JA. Neuropathology of dementia disorders. Continuum (Minneap Minn). 2022;28:834–51.
Soto C, Pritzkow S. Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases. Nat Neurosci. 2018;21:1332–40.
Mrdjen D, Fox EJ, Bukhari SA, et al. The basis of cellular and regional vulnerability in Alzheimer’s disease. Acta Neuropathol. 2019;138:729–49.
Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer’s disease. Neurotherapeutics. 2022;19:173–85.
Cummings J, Lee G, Nahed P, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement (N Y). 2022;8:e12295.
Brayne C, Richardson K, Matthews FE, et al. Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75s cohort (CC75C) study. J Alzheimers Dis. 2009;18:645–58.
White LR, Edland SD, Hemmy LS, et al. Neuropathologic comorbidity and cognitive impairment in the Nun and Honolulu-Asia aging studies. Neurology. 2016;86:1000–8.
Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982;217:408–14.
Bowen DM, Smith CB, White P, Davison AN. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 1976;99:459–96.
Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet. 1976;2:1403.
Mesulam M. A horseradish peroxidase method for the identification of the efferents of acetyl cholinesterase-containing neurons. J Histochem Cytochem. 1976;24:1281–5.
Whitehouse PJ, Price DL, Clark AW, Coyle JT, DeLong MR. Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981;10:122–6.
Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol. 1974;30:113–21.
Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia. Alzheimer type N Engl J Med. 1986;315:1241–5.
Knight R, Khondoker M, Magill N, Stewart R, Landau S. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45:131–51.
Cacabelos R, Takeda M, Winblad B. The glutamatergic system and neurodegeneration in dementia: preventive strategies in Alzheimer’s disease. Int J Geriatr Psychiatry. 1999;14:3–47.
Binvignat O, Olloquequi J. Excitotoxicity as a target against neurodegenerative processes. Curr Pharm Des. 2020;26:1251–62.
Andersen JV, Markussen KH, Jakobsen E, et al. Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration. Neuropharmacology. 2021;196:108719.
Xia P, Chen HS, Zhang D, Lipton SA. Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J Neurosci. 2010;30:11246–50.
Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer’s disease. Alzheimers Dement. 2007;3:7–17.
Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68:991–8.
Atri A, Hendrix SB, Pejović V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer’s dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7:28.
Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease. Drug Des Devel Ther. 2016;10:3267–79.
Zhang Q, Aldridge GM, Narayanan NS, Anderson SW, Uc EY. Approach to cognitive impairment in Parkinson’s disease. Neurotherapeutics. 2020;17:1495–510.
Chen JH, Huang TW, Hong CT. Cholinesterase inhibitors for gait, balance, and fall in Parkinson disease: a meta-analysis. NPJ Parkinsons Dis. 2021;7:103.
Sun C, Armstrong MJ. Treatment of Parkinson’s disease with cognitive impairment: current approaches and future directions. Behav Sci (Basel). 2021;11:54.
Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging. 2007;2:327–35.
Matsunaga S, Kishi T, Yasue I, Iwata N. Cholinesterase inhibitors for lewy body disorders: a meta-analysis. Int J Neuropsychopharmacol. 2015;19:pyv086.
Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Curr Treat Options Neurol. 2014;16:319.
Brennan L, Pantelyat A, Duda JE, et al. Memantine and cognition in Parkinson’s disease dementia/dementia with lewy bodies: a meta-analysis. Mov Disord Clin Pract. 2016;3:161–7.
Medoro A, Bartollino S, Mignogna D, et al. Complexity and selectivity of γ-secretase cleavage on multiple substrates: consequences in Alzheimer’s disease and cancer. J Alzheimers Dis. 2018;61:1–15.
Hur JY. γ-secretase in Alzheimer’s disease. Exp Mol Med. 2022;54:433–46.
Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer’s disease Therapeutics. Drugs. 2023;83:569–76.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512–27.
Söderberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical Trials for Alzheimer’s disease. Neurotherapeutics. 2023;20:195–206.
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537:50–6.
Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4:887–93.
Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer’s disease. Alzheimers Dement (N Y). 2021;7:e12112.
Shi M, Chu F, Zhu F, Zhu J. Impact of anti-amyloid-β monoclonal antibodies on the pathology and clinical profile of Alzheimer’s disease: a focus on aducanumab and lecanemab. Front Aging Neurosci. 2022;14:870517.
Salloway S, Chalkias S, Barkhof F, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol. 2022;79:13–21.
Herring WJ, Ceesay P, Snyder E, et al. Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial. Alzheimers Dement. 2020;16:541–51.
Mansuri Z, Reddy A, Vadukapuram R, Trivedi C, Amara A. Pimavanserin in the treatment of Parkinson’s disease psychosis: meta-analysis and meta-regression of randomized clinical trials. Innov Clin Neurosci. 2022;19:46–51.
Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y). 2023;9: e12385.
Cummings J. New approaches to symptomatic treatments for Alzheimer’s disease. Mol Neurodegener. 2021;16:2.
Vaz M, Silvestre S. Alzheimer’s disease: Recent treatment strategies. Eur J Pharmacol. 2020;887:173554.
Weihofen A, Liu Y, Arndt JW, et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson’s disease models. Neurobiol Dis. 2019;124:276–88.
Liu P, Wang Y, Sun Y, Peng G. Neuroinflammation as a potential therapeutic target in Alzheimer’s disease. Clin Interv Aging. 2022;17:665–74.
Latimer CS, Lucot KL, Keene CD, Cholerton B, Montine TJ. Genetic insights into Alzheimer’s disease. Annu Rev Pathol. 2021;16:351–76.
Novikova G, Kapoor M, Tcw J, et al. Integration of Alzheimer’s disease genetics and myeloid genomics identifies disease risk regulatory elements and genes. Nat Commun. 2021;12:1610.
DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139(Suppl 2):136–53.
Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID exposure and risk of Alzheimer’s disease: an updated meta-analysis from cohort studies. Front Aging Neurosci. 2018;10:83.
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14:388–405.
Zhao S, Mysler E, Moots RJ. Etanercept for the treatment of rheumatoid arthritis. Immunotherapy. 2018;10:433–45.
De Sousa Rodrigues ME, Houser MC, Walker DI, et al. Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer’s disease associated with obesity, metabolic syndrome, and type 2 diabetes. Alzheimers Res Ther. 2019;12:1.
Torres-Acosta N, O’Keefe JH, O’Keefe EL, Isaacson R, Small G. Therapeutic potential of TNF-α inhibition for Alzheimer’s disease prevention. J Alzheimers Dis. 2020;78:619–26.
Wang X, Sun G, Feng T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res. 2019;29:787–803.
Rao Y. Omission of previous publications by an author should be corrected. Cell Res. 2020;30:819.
Costa MJF, de Araújo IDT, da Rocha AL, et al. Relationship of Porphyromonas gingivalis and Alzheimer’s disease: a systematic review of pre-clinical studies. Clin Oral Investig. 2021;25:797–806.
Arastu-Kapur S, Nguyen M, Raha D, et al. Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. Pharmacol Res Perspect. 2020;8:e00562.
Costa M, Páez A. Emerging insights into the role of albumin with plasma exchange in Alzheimer’s disease management. Transfus Apher Sci. 2021;60:103164.
Hannestad J, Duclos T, Chao W, et al. Safety and tolerability of GRF6019 infusions in severe Alzheimer’s disease: a phase II double-blind placebo-controlled trial. J Alzheimers Dis. 2021;81:1649–62.
Doroszkiewicz J, Mroczko B. New possibilities in the therapeutic approach to Alzheimer’s disease. Int J Mol Sci. 2022;23:8902.
Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2018;18:225–42.
Mehl LC, Manjally AV, Bouadi O, Gibson EM, Tay TL. Microglia in brain development and regeneration. Development. 2022;149:dev200425.
Yu F, Wang Y, Stetler AR, et al. Phagocytic microglia and macrophages in brain injury and repair. CNS Neurosci Ther. 2022;28:1279–93.
Borst K, Dumas AA, Prinz M. Microglia: I=immune and non-immune functions. Immunity. 2021;54:2194–208.
Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23:1018–27.
Blinzinger K, Kreutzberg G. Displacement of synaptic terminals from regenerating motoneurons by microglial cells. Z Zellforsch Mikrosk Anat. 1968;85:145–57.
Cockram TOJ, Dundee JM, Popescu AS, Brown GC. The phagocytic code regulating phagocytosis of mammalian cells. Front Immunol. 2021;12:629979.
Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016;17:201–7.
Wang S, Mustafa M, Yuede CM, et al. Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model. J Exp Med. 2020;217:e20200785.
Werneburg S, Jung J, Kunjamma RB, et al. Targeted complement inhibition at synapses prevents microglial synaptic engulfment and synapse loss in demyelinating disease. Immunity. 2020;52:167-182.e7.
Litvinchuk A, Wan YW, Swartzlander DB, et al. Complement C3aR inactivation attenuates Tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer’s disease. Neuron. 2018;100:1337-1353.e5.
Anwar S, Pons V, Rivest S. Microglia purinoceptor P2Y6: an emerging therapeutic target in CNS diseases. Cells. 2020;9:1595.
Elmore MR, Lee RJ, West BL, Green KN. Characterizing newly repopulated microglia in the adult mouse: impacts on animal behavior, cell morphology, and neuroinflammation. PLoS ONE. 2015;10:e0122912.
Basilico B, Ferrucci L, Khan A, et al. What microglia depletion approaches tell us about the role of microglia on synaptic function and behavior. Front Cell Neurosci. 2022;16:1022431.
Graykowski D, Cudaback E. Don’t know what you got till it’s gone: microglial depletion and neurodegeneration. Neural Regen Res. 2021;16:1921–7.
Mancuso R, Fryatt G, Cleal M, et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 2019;142:3243–64.
Romero-Molina C, Navarro V, Jimenez S, et al. Should we open fire on microglia? Depletion models as tools to elucidate microglial role in health and Alzheimer’s disease. Int J Mol Sci. 2021;22:9734.
Li X, Zhu H, Sun X, et al. Human neural stem cell transplantation rescues cognitive defects in APP/PS1 model of Alzheimer’s disease by enhancing neuronal connectivity and metabolic activity. Front Aging Neurosci. 2016;8:282.
Jeyakumar M, Lee JP, Sibson NR, et al. Neural stem cell transplantation benefits a monogenic neurometabolic disorder during the symptomatic phase of disease. Stem Cells. 2009;27:2362–70.
Yang Y, Aloi MS, Cudaback E, et al. Wild-type bone marrow transplant partially reverses neuroinflammation in progranulin-deficient mice. Lab Invest. 2014;94:1224–36.
Yang Y, Cudaback E, Jorstad NL, et al. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. Am J Pathol. 2013;183:905–17.
Das MM, Godoy M, Chen S, et al. Young bone marrow transplantation preserves learning and memory in old mice. Commun Biol. 2019;2:73.
El-Akabawy G, Aabed K, Rashed LA, et al. Preventive effects of bone marrow-derived mesenchymal stem cell transplantation in a D-galactose-induced brain aging in rats. Folia Morphol (Warsz). 2022;81:632–49.
Li C, Chen YH, Zhang K. Neuroprotective properties and therapeutic potential of bone marrow-Derived microglia in Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2020;35:1533317520927169.
Han F, Bi J, Qiao L, Arancio O. Stem cell therapy for Alzheimer’s disease. Adv Exp Med Biol. 2020;1266:39–55.
Bae JS, Jin HK, Lee JK, Richardson JC, Carter JE. Bone marrow-derived mesenchymal stem cells contribute to the reduction of amyloid-β deposits and the improvement of synaptic transmission in a mouse model of pre-dementia Alzheimer’s disease. Curr Alzheimer Res. 2013;10:524–31.
Wang YK, Zhu WW, Wu MH, et al. Human clinical-grade parthenogenetic ESC-derived dopaminergic neurons recover locomotive defects of nonhuman primate models of Parkinson’s disease. Stem Cell Reports. 2018;11:171–82.
Sivandzade F, Cucullo L. Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int J Mol Sci. 2021;22:2153.
Brody M, Agronin M, Herskowitz BJ, et al. Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer’s disease. Alzheimers Dement. 2023;19:261–73.
Piao J, Zabierowski S, Dubose BN, et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell. 2021;28:217-229.e7.
Cecerska-Heryć E, Pękała M, Serwin N, et al. The use of stem cells as a potential treatment method for selected neurodegenerative diseases: review. Cell Mol Neurobiol. 2023;2643–73.
Hoang DM, Pham PT, Bach TQ, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7:272.
Rosser AE, Busse ME, Gray WP, et al. Translating cell therapies for neurodegenerative diseases: Huntington’s disease as a model disorder. Brain. 2022;145:1584–97.
NIA. Advancing research on Alzheimer’s disease (AD) and AD-related dementias (ADRD) (R41/R42 clinical trial optional). Health and Human Services. 2023. https://grants.nih.gov/grants/guide/pa-files/PAS-22-197.html. Accessed 19 Sept 2023.
U.S. Food and Drug Administration. Considerations for developing the indications and usage section of prescription drug labeling. 2017. https://www.fda.gov/media/109300/download. Accessed 19 Sept 2023.
Turgeon J, Michaud V, Steffen L. The dangers of polypharmacy in elderly patients. JAMA Intern Med. 2017;177:1544.
Latimer CS, Burke BT, Liachko NF, et al. Resistance and resilience to Alzheimer’s disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. Acta Neuropathol Commun. 2019;7:91.
SantaCruz KS, Sonnen JA, Pezhouh MK, et al. Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. J Neuropathol Exp Neurol. 2011;70:832–40.
Montine TJ, Corrada MM, Kawas C, et al. Association of cognition and dementia with neuropathologic changes of Alzheimer disease and other conditions in the oldest-old. Neurology. 2022;99:e1067–78.
White LR, Corrada MM, Kawas CH, et al. Neuropathologic changes of Alzheimer’s disease and related dementias: relevance to future prevention. J Alzheimers Dis. 2023;307–16.
Kovacs GG, Milenkovic I, Wöhrer A, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126:365–84.
Rahimi J, Kovacs GG. Prevalence of mixed pathologies in the aging brain. Alzheimers Res Ther. 2014;6:82.
Boyle PA, Yang J, Yu L, et al. Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline. Brain. 2017;140:804–12.
Sin MK, Cheng Y, Roseman JM, et al. Characteristics and predictors of Alzheimer’s disease resilience phenotype. J Clin Med. 2023;12:2463.
Beach TG, Malek-Ahmadi M. Alzheimer’s disease neuropathological comorbidities are common in the younger-old. J Alzheimers Dis. 2021;79:389–400.
Custodio N, Montesinos R, Lira D, et al. Mixed dementia: a review of the evidence. Dement Neuropsychol. 2017;11:364–70.
Nag S, Yu L, Capuano AW, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol. 2015;77:942–52.
Nelson PT, Brayne C, Flanagan ME, et al. Frequency of LATE neuropathologic change across the spectrum of Alzheimer’s disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts. Acta Neuropathol. 2022;144:27–44.
Ferman TJ, Aoki N, Crook JE, et al. The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies. Alzheimers Dement. 2018;14:330–9.
Liu KY, Reeves S, McAleese KE, et al. Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer’s disease. Brain. 2020;143:3842–9.
Thal DR, Tomé SO. The central role of tau in Alzheimer’s disease: from neurofibrillary tangle maturation to the induction of cell death. Brain Res Bull. 2022;190:204–17.
Funding
This work was supported by NIH grants AG053983 and AG057707 (TJM and LRW, MPIs).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
All authors have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Perna, A., Montine, K.S., White, L.R. et al. Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia. Neurotherapeutics 20, 1641–1652 (2023). https://doi.org/10.1007/s13311-023-01441-w
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13311-023-01441-w